Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

Journal of Urology

Volumn 169, Issue 6, 2003, Pages 2008-2012

  Smith, Matthew R ^a   Eastham, James ^a   Gleason, Donald M ^a   Shasha, Daniel ^a   Tchekmedyian, Simon ^a   Zinner, Norman ^a  

^a NONE

Author keywords

Bone density; Diphosphonates; Osteoporosis; Prostatic neoplasms

Indexed keywords

PLACEBO; ZOLEDRONIC ACID;

ADULT; AGED; ANDROGEN THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE DISEASE; BONE MINERAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSURIA; ERECTILE DYSFUNCTION; FATIGUE; FEMUR NECK; HEMATURIA; HIP; HOT FLUSH; HUMAN; LIMB PAIN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MUSCLE WEAKNESS; NOCTURIA; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING; URINARY FREQUENCY;

EID: 0038075478     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000063820.94994.95     Document Type: Article

References (10)

1. Ross, R. W. and Small, E. J.: Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol, 167: 1952, 2002
2. Oefelein, M. G., Ricchiuti, V., Conrad, W. and Resnick, M. I.: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol, 168: 1005, 2002
3. Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U. et al: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med, 346: 653, 2002
4. Orwoll, E.: Assessing bone density in men. J Bone Miner Res, 15: 1867, 2000
5. Smith, M. R., McGovern, F. J., Fallon, M. A., Schoenfeld, D., Kantoff, P. W. and Finkelstein, J. S.: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer, 91: 2238, 2001
6. Wei, J. T., Gross, M., Jaffe, C. A., Gravlin, K., Lahaie, M., Faerber, G. J. et al: Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology, 54: 607, 1999
7. Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A. et al: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 345: 948, 2001
8. Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D. et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol, 19: 558, 2001
9. Dawson-Hughes, B., Harris, S. S., Krall, E. A. and Dallal, G. E.: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med, 337: 670, 1997
10. Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L. et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst, 94: 1458, 2002